Related Experiment Video
Updated: May 13, 2026
06:13
The Intra-Aortic Balloon Pump
Published on: February 5, 2021
Utilization of Beta blockers post-myocardial infarction
W M Ong1, S Che Zuraini, W A Wan Azman
1Ministry of Health Malaysia, Pharmaceutical Services Division, Ministry of Health Malaysia, Lot 36, Jalan Universiti, 46350 Petaling Jaya, Selangor, Malaysia. woon_may@moh.gov.my.
The Medical Journal of Malaysia
|March 8, 2013
Summary
Beta blockers benefit heart attack survivors, but are often underused or undertreated. This study found many post-myocardial infarction patients received suboptimal beta-blocker dosages, highlighting a need for improved prescribing practices.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Beta blockers are crucial for reducing morbidity and mortality in post-myocardial infarction (MI) patients.
- Despite proven benefits, beta-blocker underuse and suboptimal dosing remain significant clinical challenges.
Purpose of the Study:
- To determine the rate of beta-blocker prescription in post-MI patients at University Malaya Medical Centre (UMMC).
- To assess the proportion of patients receiving optimal beta-blocker dosages.
- To identify factors associated with beta-blocker prescribing patterns post-MI.
Main Methods:
- Retrospective observational study design.
- Review of 315 patient case notes from University Malaya Medical Centre (UMMC).
- Analysis of beta-blocker prescription rates, dosage optimization, and associated patient factors.
Main Results:
- Beta blockers were prescribed to 77.5% of post-MI patients.
- Optimal beta-blocker dosages were achieved in only 39.3% of patients.
- Factors associated with reduced prescribing included advanced age, low ejection fraction, history of CVA, mild asthma, and concurrent use of CCB, digoxin, or anti-asthmatics.
Conclusions:
- Significant underuse and suboptimal dosing of beta blockers exist in post-MI patients.
- Specific patient populations require targeted interventions to improve beta-blocker utilization.
- Intensified efforts are needed to optimize beta-blocker dosages to levels proven effective in clinical trials.
Related Concept Videos
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
01:28Antihypertensive Drugs: Types of β-Blockers
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
01:14Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
01:16Antianginal Drugs: Nitrates and β-Blockers
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...